CXCR4-targeted PEGylated PLGA NPs could co-deliver sorafenib and metapristone into HCC, thereby enhancing cytotoxicity and synergistically suppressing HCC proliferation and resistance. The gene discussed is CXCR4; the disease is hepatocellular carcinoma.